Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.42 |
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | CA12 | O43570 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23378605 | 0.94 | CA1 (0.43) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL25144505 | 0.86 | CA1 (0.40) | CA1CA2CA9CA12LMNA | |
| SCHEMBL5745513 | 0.85 | CA1 (0.40) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL23840832 | 0.85 | CA1 (0.38) | CA1CA2CA9CA12LMNA | |
| SCHEMBL23840833 | 0.85 | CA1 (0.38) | CA1CA2CA9CA12LMNA | |
| SCHEMBL9939356 | 0.83 | ALDH1A1 (0.39) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL2705851 | 0.82 | ALDH1A1 (0.48) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL2705849 | 0.82 | ALDH1A1 (0.48) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL8914013 | 0.82 | ALDH1A1 (0.48) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL1296897 | 0.82 | ALDH1A1 (0.48) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CA1 356/4885CA2 209/4885CA9 361/4885 |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | CA1 2920/4885CA2 4262/4885CA9 4056/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | CA1 4679/4885CA2 4684/4885CA9 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.